[Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone].

Authors

Kang He Zheng, Camiel L M de Roij van Zuijdewijn, Loek van Heerebeek, Michiel A van Agtmael

Published in

Nederlands tijdschrift voor geneeskunde. Volume 170. Jun 11, 2026. Epub Jun 11, 2026.

Abstract

Patients with chronic kidney disease (CKD) and metabolic diseases including type 2 diabetes mellitus (T2DM) have an increased cardiovascular risk. Mineralocorticoid receptor overactivation plays a key role in inflammation and fibrosis in heart and kidneys.
To review the clinical evidence and provide practical guidance on selecting mineralocorticoid receptor antagonists (MRAs) in cardiovascular-kidney-metabolic syndrome.
Finerenone reduced kidney and cardiovascular events in patients with T2DM (FIDELIO-DKD, FIGARO-DKD). The CONFIDENCE trial showed reduction of proteinuria when combining finerenone with empagliflozin. Outcome studies are lacking for spironolactone and eplerenone. In heart failure with preserved ejection fraction (HFpEF), FINEARTS-HF demonstrated cardiovascular benefits with finerenone, while TOPCAT with spironolactone showed mixed results. In the Netherlands, finerenone uptake remains limited despite regulatory approval.
Finerenone offers proven efficacy in CKD and DM2. For treatment-resistant hypertension, classic steroidal MRA's remain valuable. Patient-specific factors including blood pressure and susceptibility to hyperkalemia can further guide MRA selection.

PMID:
42294746
Bibliographic data and abstract were imported from PubMed on 15 Jun 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.